Obio Technology (Shanghai) Past Earnings Performance
Past criteria checks 0/6
Obio Technology (Shanghai)'s earnings have been declining at an average annual rate of -20.6%, while the Life Sciences industry saw earnings growing at 21.9% annually. Revenues have been growing at an average rate of 20.9% per year.
Key information
-20.6%
Earnings growth rate
14.8%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 20.9% |
| Return on equity | -6.9% |
| Net Margin | -59.2% |
| Next Earnings Update | 29 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Obio Technology (Shanghai) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 234 | -138 | 116 | 53 |
| 31 Dec 23 | 205 | -128 | 106 | 51 |
| 30 Sep 23 | 213 | -66 | 102 | 50 |
| 30 Jun 23 | 240 | -26 | 93 | 45 |
| 31 Mar 23 | 249 | -5 | 90 | 39 |
| 31 Dec 22 | 291 | 39 | 89 | 35 |
| 30 Sep 22 | 306 | 59 | 85 | 32 |
| 30 Jun 22 | 291 | 59 | 82 | 29 |
| 31 Mar 22 | 281 | 57 | 79 | 28 |
| 31 Dec 21 | 255 | 54 | 69 | 24 |
| 30 Sep 21 | 231 | 52 | 60 | 18 |
| 31 Dec 20 | 143 | 94 | 52 | 22 |
| 31 Dec 19 | 63 | -37 | 47 | 24 |
| 30 Jun 19 | 52 | -38 | 51 | 22 |
| 31 Mar 19 | 47 | -33 | 44 | 21 |
| 31 Dec 18 | 44 | -32 | 37 | 20 |
| 30 Sep 18 | 39 | -23 | 31 | 16 |
| 30 Jun 18 | 35 | -18 | 25 | 13 |
| 31 Mar 18 | 31 | -19 | 24 | 12 |
| 31 Dec 17 | 28 | -20 | 23 | 11 |
| 30 Sep 17 | 25 | -14 | 23 | 8 |
| 30 Jun 17 | 23 | -9 | 23 | 4 |
| 31 Mar 17 | 21 | -8 | 25 | 2 |
| 31 Dec 16 | 20 | -7 | 26 | 0 |
| 31 Dec 15 | 14 | -1 | 12 | 0 |
| 31 Dec 14 | 8 | -4 | 9 | 0 |
Quality Earnings: 688238 is currently unprofitable.
Growing Profit Margin: 688238 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688238 is unprofitable, and losses have increased over the past 5 years at a rate of 20.6% per year.
Accelerating Growth: Unable to compare 688238's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688238 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (0.7%).
Return on Equity
High ROE: 688238 has a negative Return on Equity (-6.86%), as it is currently unprofitable.